ANNOUNCEMENT

NOBEL PRIZE 2026

This year's laureates, their fields, and the discoveries that earned them the prize.Live nowSee the winners
Moonbase
← Back to Awards
NIHNATIONAL CANCER INSTITUTER01

Generating Synthetic Lethality in Glioblastoma with a First-In-Class Non-Muscle Myosin II Inhibitor

Active
Institution
MAYO CLINIC JACKSONVILLE, FL
Principal investigator
Steven S Rosenfeld
Funding
$608K
Duration
2025–2029
Open portfolio

Moonbase score

Still being scored

Abstract

PROJECT SUMMARY/ABSTRACT We have shown that in addition to being irreplaceable for glioblastoma (GBM) invasion and mitosis, members of the non-muscle myosin II (NMII) family of molecular motors also regulate oncogenic signaling, mitochondrial homeostasis, and reactive oxygen formation. This suggests that targeting the two predominant NMII isoforms in GBM (NMIIA and IIB) will synergize with signal transduction inhibitors and with therapies that depend on reactive oxygen, including radiation. We find that MT-125, a non-toxic, CNS permeant small molecule inhibitor of NMIIA and NMIIB prolongs median survival by ~30% as a single agent. Furthermore, when it is combined with sunitinib, a multi-RTK inhibitor, MT-125 prolongs median survival nearly 2-fold over vehicle and produces long term, tumor-free remissions in nearly half of mice. In addition, MT-125 sensitizes GBMs to radiotherapy. Our central hypothesis is that by uncovering the mechanisms for these remarkable forms of synergy between MT-125, signaling inhibitors, and radiation therapy, we can optimize the use of this highly novel therapeutic in studies that should lay the groundwork for first-in-human clinical trials.

Research team

  • Peter CanollPI
  • Steven S RosenfeldPI

LOADING MOONBASE SCORE

R01NATIONAL CANCER INSTITUTEClinical Neuroimmunology and Brain Tumors Study Section[CNBT]glioblastomamedianmyosinmedian survivalreactivereactive oxygeninhibitorgbm

Questions for MAYO CLINIC JACKSONVILLE

Answered by the team behind this research.

No questions yet. Sign in to ask the first one

Related grants

Same researchers, same institution, same topic, scored first.